TY  - GEN
AU  - Weekes,Colin D
AU  - Von Hoff,Daniel D
AU  - Adjei,Alex A
AU  - Leffingwell,Diane P
AU  - Eckhardt,S Gail
AU  - Gore,Lia
AU  - Lewis,Karl D
AU  - Weiss,Glen J
AU  - Ramanathan,Ramesh K
AU  - Dy,Grace K
AU  - Ma,Wen W
AU  - Sheedy,Beth
AU  - Iverson,Cory
AU  - Miner,Jeffrey N
AU  - Shen,Zancong
AU  - Yeh,Li-Tain
AU  - Dubowy,Ronald L
AU  - Jeffers,Michael
AU  - Rajagopalan,Prabhu
AU  - Clendeninn,Neil J
TI  - Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
SN  - 1557-3265
PY  - 2013///1031
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Cohort Studies
KW  - Diphenylamine
KW  - analogs & derivatives
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Mitogen-Activated Protein Kinase 1
KW  - antagonists & inhibitors
KW  - Neoplasm Staging
KW  - Neoplasms
KW  - drug therapy
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - pharmacokinetics
KW  - Sulfonamides
KW  - Tissue Distribution
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-12-3529
ER  -